📊 IOBT Key Takeaways
Is IOBT a Good Investment? Thesis Analysis
IO Biotech is a pre-revenue pharmaceutical company with severe financial distress, burning $61.4M in operating cash flow with only $30.7M in cash reserves, indicating a runway of approximately 6 months. The company's negative net income of -$57.0M, combined with a debt-to-equity ratio of 18.29x and stockholders' equity of only $911K, suggests imminent solvency concerns and substantial dilution risk for existing shareholders.
Why Buy IOBT? Key Strengths
- Adequate short-term liquidity with current ratio of 2.01x providing temporary operational flexibility
- Substantial cash position of $30.7M relative to total assets, though insufficient relative to burn rate
- No insider selling activity in last 90 days suggests management confidence, though absence of insider buying is notable
IOBT Investment Risks to Consider
- Severe cash burn of $61.4M annually with only 6 months of runway at current rate, creating critical funding risk
- Pre-revenue status with no commercial product monetization despite operating as a pharmaceutical company
- Extremely high leverage with debt-to-equity of 18.29x and minimal equity cushion of $911K, indicating bankruptcy risk if cash depletes
- Negative interest coverage of -215.6x shows inability to service debt from operations
- Operating losses of -$65.1M demonstrate fundamental business model failure without path to profitability
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to assess immediate solvency timeline
- Clinical trial progress and regulatory milestones that could support future revenue potential
- Additional financing activities and dilution impact on existing shareholders
- Operating cash flow trajectory and quarterly burn rate changes
IOBT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.01x current ratio provides a solid financial cushion.
IOBT Profitability Ratios
IOBT vs Healthcare Sector
How IO Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IOBT Overvalued or Undervalued?
Based on fundamental analysis, IO Biotech, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IOBT Balance Sheet & Liquidity
IOBT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IO Biotech, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.98 indicates the company is currently unprofitable.
IOBT Growth Metrics (YoY)
IOBT Capital Allocation
IOBT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IO Biotech, Inc. (CIK: 0001865494)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IOBT
What is the AI rating for IOBT?
IO Biotech, Inc. (IOBT) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IOBT's key strengths?
Claude: Adequate short-term liquidity with current ratio of 2.01x providing temporary operational flexibility. Substantial cash position of $30.7M relative to total assets, though insufficient relative to burn rate.
What are the risks of investing in IOBT?
Claude: Severe cash burn of $61.4M annually with only 6 months of runway at current rate, creating critical funding risk. Pre-revenue status with no commercial product monetization despite operating as a pharmaceutical company.
What is IOBT's revenue and growth?
IO Biotech, Inc. reported revenue of N/A.
Does IOBT pay dividends?
IO Biotech, Inc. does not currently pay dividends.
Where can I find IOBT SEC filings?
Official SEC filings for IO Biotech, Inc. (CIK: 0001865494) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IOBT's EPS?
IO Biotech, Inc. has a diluted EPS of $-0.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IOBT a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, IO Biotech, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IOBT stock overvalued or undervalued?
Valuation metrics for IOBT: ROE of -6,258.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IOBT stock in 2026?
Our dual AI analysis gives IO Biotech, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IOBT's free cash flow?
IO Biotech, Inc.'s operating cash flow is $-61.4M, with capital expenditures of $58.0K.
How does IOBT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -6,258.6% (avg: 15%), current ratio 2.01 (avg: 2).